Endpoints NewsOriginal article
Atara, Pierre Fabre's cell therapy to get another shot at FDA approval
RegulatoryPositive
AI Analysis
Summary
Atara Biotherapeutics and Pierre Fabre's T cell therapy, which has been rejected twice, is getting another opportunity for FDA approval as regulators are willing to reconsider using the Phase 3 study as the basis for approval.
Clinical Trial Data
Phase
Phase 3
Outcome Details
US regulators willing to reconsider Phase 3 study as basis for approval after two previous rejections
Importance:7/10
Sentiment:
0.60
cell therapyT cell therapyFDA approvalresubmissionregulatory reconsideration
Related Companies
Read the original article
Published by Endpoints News on May 7, 2026 1:17 PM